rotation.to
Following this device: dark.
Free account
rotation.to
Appearance
Following this device: dark.
Drag a card by its title · ⚙ to size, swap or remove

The company

Danaher Corporation

DHR · NYSE

Health CareLife-science toolsJust started movingAI

DHR stood above a rising 150-day average in 18 of the last 52 weekly readings, including each of the last 2 weeks. It is 17.2% above that average now. Life Science Tools & Research Services: 52% of its 79 stocks in an uptrend (+4 points in four weeks); Health Care: 25% (−11 points in four weeks).

Statistics

Rotation
Just started moving
Weeks in an uptrend
2 in a row
Industry in uptrend
52% +4 in 4 wk
Insider buys, 12 months
$0
Insider sales, 12 months
$271.1M
Officials’ trades on record
172

In the rotation

Each square a week: lit when it closed above a rising 150-day average. 18 of 52 weeks.

17 Apr – 16 Oct
26%41%57%Apr 26Jun 26Jul 26Sep 26Oct 26

Life-science tools: About half its stocks are in an uptrend and the share has been climbing. Health Care: A minority of its stocks are in an uptrend and the share has fallen sharply over four weeks.

Money in and out

1 Nov 2024 – 1 Oct 2026
−$237.1M$0Nov 24May 25Nov 25Apr 26Oct 26

Open-market buys above the line and sales below, in dollars. Not yet read: institutions.

Congress and officials

172 disclosed lines: House 111, Senate 35, executive 26; 52 people.

WhoDidAmountTraded
Kevin Hern House: U.S. House ClerkOK01soldjoint$1k–$15k2 Sep 2026filed 25 Sep 2026
Kevin Hern House: U.S. House ClerkOK01soldjoint$15k–$50k31 Aug 2026filed 25 Sep 2026
Donald J. Trump Executive branch: Office of Government EthicsWhite House Officebought$50k–$100k27 Jul 2026filed 22 Sep 2026
Donald J. Trump Executive branch: Office of Government EthicsWhite House Officebought$100k–$250k23 Jul 2026filed 22 Sep 2026
Donald J. Trump Executive branch: Office of Government EthicsWhite House Officebought$100k–$250k20 Jul 2026filed 22 Sep 2026
Donald J. Trump Executive branch: Office of Government EthicsWhite House Officebought$1k–$15k8 Jul 2026filed 22 Sep 2026
Donald J. Trump Executive branch: Office of Government EthicsWhite House Officebought$1k–$15k23 Jun 2026filed 22 Aug 2026
Donald J. Trump Executive branch: Office of Government EthicsWhite House Officesold$15k–$50k22 May 2026filed 1 Jul 2026
Donald J. Trump Executive branch: Office of Government EthicsWhite House Officesold$50k–$100k18 May 2026filed 1 Jul 2026
Donald J. Trump Executive branch: Office of Government EthicsWhite House Officesold$1k–$15k18 May 2026filed 1 Jul 2026
Donald J. Trump Executive branch: Office of Government EthicsWhite House Officesold$100k–$250k11 May 2026filed 1 Jul 2026
Donald J. Trump Executive branch: Office of Government EthicsWhite House Officesold$15k–$50k5 May 2026filed 1 Jul 2026

Insiders

Buy orders, 12 months0
Sale orders, 12 months10
Buyers · sellers0 · 8
WhoDidSharesTraded
Rainer BlairPresident & CEOsold11,307at $217.7721 Aug 2026filed 24 Aug 2026
Rainer BlairPresident & CEOsold39,193at $218.7321 Aug 2026filed 24 Aug 2026
Rainer BlairPresident & CEOsold7,755at $219.3521 Aug 2026filed 24 Aug 2026
Alan G. SpoonDirectorsold1,358at $174.671 May 2026filed 4 May 2026
Gregory M. MilosevichExecutive Vice Presidentsold1,320at $208.0119 Feb 2026filed 20 Feb 2026

Lines filed since 2 January 2026, newest first; every insider’s older lines are on their own page.

Institutions

Still reading this part; it fills in a moment.

Everyone who traded it

Mitchell P. Rales Company insiderChairman of Exec. Committee · last 9 Oct 20269 · 7
Steven M. Rales Company insiderChairman · last 9 Oct 20260 · 7
Kevin Hern HouseOK01 · last 2 Sep 20264 · 3
Rainer Blair Company insiderPresident & CEO · last 21 Aug 20260 · 11
Christopher Bouda Company insiderVP, Chief Accounting Officer · last 4 Aug 20260 · 0
Christopher Paul Riley Company insiderExecutive Vice President · last 4 Aug 20260 · 1
Gregory M. Milosevich Company insiderExecutive Vice President · last 4 Aug 20260 · 1
Jonathan Leiken Company insiderSVP-Chief Legal Officer · last 4 Aug 20260 · 0
Jose-Carlos Gutierrez-Ramos Company insiderSVP, Chief Science Officer · last 4 Aug 20260 · 2
Matthew E. Gugino Company insiderEVP & Chief Financial Officer · last 4 Aug 20260 · 0
Montgomery Julie A. Sawyer Company insiderExecutive Vice President · last 4 Aug 20260 · 0
A. Shane Sanders Company insiderDirector · last 31 Jul 20260 · 0

Same industry

OABI OmniAbLeading+65%
TXG 10x GenomicsLeading+60%
AVTR AvantorLeading+47%
ILMN IlluminaLeading+44%
RVTY RevvityLeading+37%
MASS 908 DevicesLeading+31%

Distance from each stock’s own 150-day average.

Government contracts

Awards1
Total$17K
Latest20 Sep 2026

From its SEC filings

Profit per saleFY 2025 · to 31 Dec 202559.1%
Operating profit marginFY 2025 · to 31 Dec 202519.1%
Free cash flow marginFY 2025 · to 31 Dec 202521.4%
Return on capital employedFY 2025 · to 31 Dec 20256.1%
Cash conversionFY 2025 · to 31 Dec 2025178%
Debt to equityFY 2025 · to 31 Dec 20250.35×
Research spendFY 2025 · to 31 Dec 20256.5%
Share count trendFY 2025 · to 2 Feb 20260.0%
Cash and equivalentsFY 2025 · to 31 Dec 2025$4.6B
Free cash flowFY 2025 · to 31 Dec 2025$5.3B

Analyst forecasts

No analyst forecasts yet.